Search

The product will be launched in March 2024 [ABSTRACT FROM AUTHOR]

The product will be launched in March 2024 [ABSTRACT FROM AUTHOR]

Glenmark's current portfolio consists of 176 products authorized for distribution in the U.S. marketplace [ABSTRACT FROM AUTHOR]

Glenmark's current portfolio consists of 176 products authorized for distribution in the U.S. marketplace [ABSTRACT FROM AUTHOR]

The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad [ABSTRACT FROM AUTHOR]

The group now has 305 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04 [ABSTRACT FROM AUTHOR]

The Gilenya Capsules, 0.5 mg market achieved annual sales of approximately $2.1 billion [ABSTRACT FROM AUTHOR]

The Gilenya Capsules, 0.5 mg market achieved annual sales of approximately $2.1 billion [ABSTRACT FROM AUTHOR]

The article reports on attainment of approval by subsidiary of pharmaceutical firm Strides Shasun as Strides Pharma Global by the U.S. Food & Drug Administration (USFDA) for development of the Fingolimod Capsules. It states expectations for introduction of capsules in generic market by February 2019. It mentions utilization of Fingolimod drugs for treatment of multiple sclerosis relapsing for among adult patients.